Evidence map›Paper›PMID 29569797›Full record

ArticleStem cells (Dayton, Ohio)2018

Follistatin-Like 3 Enhances the Function of Endothelial Cells Derived from Pluripotent Stem Cells by Facilitating β-Catenin Nuclear Translocation Through Inhibition of Glycogen Synthase Kinase-3β Activity.

Sophia Kelaini, Marta Vilà-González, Rachel Caines, David Campbell, Magdalini Eleftheriadou, Marianna Tsifaki, Corey Magee, Amy Cochrane, Karla O'neill, Chunbo Yang and 4 more

Abstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Norrie disease protein is essential for cochlear hair cell maturation.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sophia KelainiCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.ORCID 0000-0002-4597-6248
Marta Vilà-GonzálezCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Rachel CainesCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
David CampbellCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Magdalini EleftheriadouCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Marianna TsifakiCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Corey MageeCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Amy CochraneCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Karla O'neillCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Chunbo YangCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Alan W StittCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Lingfang ZengCardiovascular Division, King's College London, London, United Kingdom.
David J GrieveCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Andriana MargaritiCentre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.ORCID 0000-0001-9303-8371

Funding

Biotechnology and Biological Sciences Research CouncilBritish Heart Foundation FS/14/35/30813British Heart Foundation FS/15/23/31435British Heart Foundation PG/14/78/31099British Heart Foundation PG/16/8/31985Medical Research Council MC_PC_16057
6 · The paper itself

Abstract

The fight against vascular disease requires functional endothelial cells (ECs) which could be provided by differentiation of induced Pluripotent Stem Cells (iPS Cells) in great numbers for use in the clinic. However, the great promise of the generated ECs (iPS-ECs) in therapy is often restricted due to the challenge in iPS-ECs preserving their phenotype and function. We identified that Follistatin-Like 3 (FSTL3) is highly expressed in iPS-ECs, and, as such, we sought to clarify its possible role in retaining and improving iPS-ECs function and phenotype, which are crucial in increasing the cells' potential as a therapeutic tool. We overexpressed FSTL3 in iPS-ECs and found that FSTL3 could induce and enhance endothelial features by facilitating β-catenin nuclear translocation through inhibition of glycogen synthase kinase-3β activity and induction of Endothelin-1. The angiogenic potential of FSTL3 was also confirmed both in vitro and in vivo. When iPS-ECs overexpressing FSTL3 were subcutaneously injected in in vivo angiogenic model or intramuscularly injected in a hind limb ischemia NOD.CB17-Prkdcscid/NcrCrl SCID mice model, FSTL3 significantly induced angiogenesis and blood flow recovery, respectively. This study, for the first time, demonstrates that FSTL3 can greatly enhance the function and maturity of iPS-ECs. It advances our understanding of iPS-ECs and identifies a novel pathway that can be applied in cell therapy. These findings could therefore help improve efficiency and generation of therapeutically relevant numbers of ECs for use in patient-specific cell-based therapies. In addition, it can be particularly useful toward the treatment of vascular diseases instigated by EC dysfunction. Stem Cells 2018;36:1033-1044.

Indexed as

Animalsbeta CateninCell DifferentiationCellular ReprogrammingFollistatin-Related ProteinsGlycogen Synthase KinasesHumansInduced Pluripotent Stem CellsMicebeta CateninFollistatin-Related ProteinsFstl3 protein, mouseGlycogen Synthase KinasesAngiogenesisCell reprogrammingFollistatin-like 3Functional endothelial cellsInduced pluripotent stem-cellsVascular disease

Identifiers

PMID29569797
PMCPMC6099345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.